|Bid||27.05 x 100|
|Ask||38.00 x 200|
|Day's Range||34.35 - 35.25|
|52 Week Range||15.25 - 35.60|
|PE Ratio (TTM)||21.49|
|Earnings Date||Jul 31, 2017 - Aug 4, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||43.25|
BioTelemetry Inc. (BEAT) enhances its position in the wireless medicine space, enlarges product profile and customer base in cardiac monitoring and diagnostic services with LifeWatch buyout.
BioTelemetry (BEAT) was a big mover last session, as the company saw its rise nearly 7% on Friday amid huge volumes.
BioTelemetry Inc. completed its previously announced acquisition of LifeWatch AG in a cash and stock deal valued at about $280 million. Both medical technology companies make products used to remotely monitor cardiac care patients. “We are gratified that LifeWatch AG shareholders embraced the immense strategic value and potential of this acquisition and moved quickly to support the BioTelemetry tender,” said Joseph H. Capper, president and CEO of Malvern-based BioTelemetry Inc., in a prepared statement.